Recurrent aphthous stomatitis (RAS), commonly known as recurrent canker sores, is the most prevalent oral mucosal disorder worldwide—and particularly widespread in China, where an estimated 10% to 25% of the population experiences recurrent episodes, according to the *Guidelines for the Diagnosis and Treatment of Recurrent Aphthous Ulcers (Trial Version)*.
These painful, shallow ulcers typically appear on the buccal mucosa, lips, tongue, or gingiva. Characterized by intense burning or stabbing pain, they significantly impair daily functions—including eating, drinking, speaking, and swallowing—often leading to nutritional compromise and reduced quality of life. While RAS is self-limiting, effective topical interventions are critical for rapid symptom control, accelerated healing, and prevention of secondary infection.
A growing body of clinical evidence supports the use of compound chamomile-lidocaine gel (marketed in China as Ganmeida®) as a multifaceted therapeutic option for mild-to-moderate RAS. This prescription-only topical gel contains three pharmacologically active components per 10 g: lidocaine hydrochloride (200 mg), thymol (10 mg), and chamomile tincture (2 g). Its mechanism of action aligns precisely with the pathophysiology of aphthous ulcers—targeting pain, inflammation, microbial colonization, and tissue repair simultaneously.
First, lidocaine hydrochloride provides rapid-onset surface anesthesia by reversibly blocking voltage-gated sodium channels in sensory nerve endings. Clinical studies confirm its superior efficacy compared with alternative topical anesthetics in dental and oral mucosal settings—offering measurable pain relief within minutes and enabling patients to resume oral intake comfortably.
Second, the antimicrobial and anti-inflammatory synergy between thymol and chamomile tincture addresses key contributors to ulcer progression. Thymol—a natural monoterpene phenol—demonstrates broad-spectrum activity against Gram-positive bacteria (including *Staphylococcus aureus*), fungi, and certain viruses. Notably, its toxicity profile is favorable: at the formulation concentration of 1.0 mg/g, it exhibits only one-quarter the systemic toxicity of phenol. Chamomile tincture complements this action through inhibition of cyclooxygenase (COX) enzymes and downstream prostaglandin synthesis, resulting in antihistaminic and anti-inflammatory effects. Together, these agents reduce perilesional erythema, edema, and warmth while lowering the risk of bacterial superinfection.
Third, emerging preclinical and clinical data indicate that Ganmeida® actively promotes mucosal regeneration. Animal studies show that the gel downregulates pro-inflammatory cytokines—including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6)—while upregulating epidermal growth factor (EGF) expression at the ulcer site. Human trials corroborate these findings: patients treated with Ganmeida® demonstrated significantly shorter time to pain resolution and complete epithelialization compared with placebo or conventional corticosteroid gels. Additional research further demonstrates enhanced efficacy when Ganmeida® is combined with *Kangfuxin liquid* (a traditional Chinese medicine preparation containing peptide-rich cockroach extract), yielding improved ulcer healing rates, reduced inflammatory burden, and lower recurrence frequency over follow-up periods.
In summary, Ganmeida® compound chamomile-lidocaine gel offers a mechanistically rational, evidence-supported approach to managing recurrent aphthous ulcers. Its triple-action profile—rapid local anesthesia, targeted antimicrobial/anti-inflammatory activity, and facilitation of mucosal repair—translates into meaningful clinical benefits: faster pain relief, accelerated wound closure, and improved functional outcomes. As a prescription medication, it should be used under the supervision of a qualified healthcare provider to ensure appropriate patient selection, dosing, and monitoring—particularly in individuals with known hypersensitivity to lidocaine or other components, or those with compromised mucosal integrity.